Entry into a Material Definitive Agreement. Term Loan Credit Facilities On August 12, 2026, Alkermes plc (the “Company”) entered into Amendment No. 1 to Credit Agreement (the “Amendment”), which amends the Credit Agreement, dated as of February 12, 2026 (the “Credit Agreement”), among the Company, as the TopCo Borrower, Alkermes, Inc., as the U.S. Borrower, Alkermes Finance LLC, as the U.S. Co-Borrower, JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Bookrunn…

President and CEO — Mr. Jackson: Mr. Jackson's responsibilities were expanded, and he was appointed as President and CEO with significant compensation and equity awards.

Results of Operatio ns and Financial Condition. On July 28, 2026, Alkermes plc (the “Company”) announced financial results for the three and six months ended June 30, 2026 and updated certain financial expectations for the year ending December 31, 2026. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on July 28, 2026 discussing such financial results and expectations are furnished herewith as Exhibit 99.1 and Exhibit 99.2,…

Termination of a Material Definitive Agreement. On July 6, 2026, Alkermes plc (the “Company”) and Amneal Pharmaceuticals LLC (“Amneal”) terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9, 2025 (the “Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Agreement. Under the Agreement, Alkermes Pharma Ireland Limited (“APIL”), a wholly-owned indirect subsidiary of the Company,…

The filing is about amendments to the stock option and incentive plan, not a management change.

Results of Operatio ns and Financial Condition. On May 5, 2026, Alkermes plc (the “Company”) announced financial results for the three months ended March 31, 2026 and updated certain financial expectations for the year ending December 31, 2026. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on May 5, 2026 discussing such financial results and expectations are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respective…

CEO — Richard F. Pops: Richard F. Pops is retiring as CEO and will be succeeded by Blair C. Jackson.

Results of Operatio ns and Financial Condition. On February 25, 2026, Alkermes plc (the “Company”) announced financial results for the three months and year ended December 31, 2025 and financial expectations for the year ending December 31, 2026. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on February 25, 2026 discussing such financial results and expectations are furnished herewith as Exhibit 99.1 and Exhibit 99.2, re…

Termination of a Material Definitive Agreement. On February 12, 2026, in connection with completion of the Acquisition (as described in

Entry into a Material Definitive Agreement. Term Loan Credit Facilities On February 12, 2026, in connection with the Acquisition (as defined below), Alkermes plc (the “Company”) entered into a credit agreement (the “Credit Agreement”), by and among Alkermes plc, as the TopCo Borrower, Alkermes, Inc., as the U.S. Borrower, Alkermes Finance LLC, as the U.S. Co-Borrower, JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Bookrunner, BofA Securities, Inc., as Joint…

Completion of Acquisition or Disposition of Assets. On February 12, 2026, the Company and Avadel Pharmaceuticals plc (“Avadel”), completed the transactions contemplated by the previously announced Transaction Agreement (the “Original Transaction Agreement”) dated October 22, 2025, as amended by Amendment No.1 to the Transaction Agreement (the “Amendment”) dated November 18, 2025, by and between the Company and Avadel (as amended, the “Transaction Agreement”). Pursuant to a court-sanctioned sc…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On February 12, 2026, the Company entered into the Credit Agreement as described under

Results of Operations and Financial Conditions. On January 12, 2026, Alkermes plc (the “Company”) made available a copy of the corporate presentation to be displayed during its presentation at the J.P. Morgan Healthcare Conference on January 13, 2026, which includes the Company’s estimated total revenues for the year ended December 31, 2025, which are preliminary, unaudited and subject to change upon completion of the Company’s review of its financial statements for the year ended December 31…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On the Amendment Date, Alkermes entered into the Amended and Restated Bridge Credit Agreement as described under

by reference, respectively. The Amendment has been filed as an exhibit herewith pursuant to the applicable rules and regulations of the SEC to provide investors with information regarding its terms. It is not intended to provide any other factual information about Alkermes, Avadel or their respective subsidiaries or affiliates or to modify or supplement any factual disclosures about Alkermes or Avadel included in their respective public reports filed with the SEC. The Amendment should not be…

Results of Operatio ns and Financial Condition. On October 28, 2025, Alkermes plc (the “Company”) announced financial results for the three and nine months ended September 30, 2025 and updated financial expectations for the year ending December 31, 2025. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on October 28, 2025 discussing such financial results and updated financial expectations are furnished herewith as Exhibit…

Entry into a Material Definitive Agreement. Transaction Agreement On October 22, 2025 (the “Agreement Date”), Alkermes plc (“Alkermes”), issued an announcement (the “Rule 2.7 Announcement”) pursuant to Rule 2.7 of the Irish Takeover Panel Act 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”) disclosing that the respective boards of directors of Alkermes and Avadel Pharmaceuticals plc, an Irish public limited company (“Avadel”), had reached an agreement on the terms of a cash and conting…

shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On the Agreement Date, Alkermes entered into the Bridge Credit Agreement as described under

Other Events. On August 15, 2025, August 27, 2025 and September 5, 2025, APIL and Alkermes, Inc., indirect wholly-owned subsidiaries of the Company, filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against each of Teva, Apotex, and MSN (each as defined herein), respectively, and on August 28, 2025, APIL and Alkermes, Inc. filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Apotex. As…

CFO — Joshua Reed: The company hired an experienced external CFO to replace an interim arrangement, which is a positive signal of stability and leadership continuity rather than a loss of a sitting executive.

Entry into a Material Definitive Agreement. On September 9, 2025, Alkermes Pharma Ireland Limited (“APIL”), a wholly-owned indirect subsidiary of Alkermes plc (the “Company”), entered into an authorized generic product supply agreement (the “AG Agreement”) with Amneal Pharmaceuticals LLC (“Amneal” and each of APIL and Amneal, a “Party”, and together, the “Parties”), pursuant to which APIL granted Amneal certain rights to distribute and sell in the United States an authorized generic version o…

Results of Operatio ns and Financial Condition. On July 29, 2025, Alkermes plc (the “Company”) announced financial results for the three and six months ended June 30, 2025. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on July 29, 2025 discussing such financial results are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. This information, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for…

The filing discloses shareholder approval of amendments to a stock incentive plan, which is a compensatory arrangement rather than a change in management personnel.

Results of Operatio ns and Financial Condition. On May 1, 2025, Alkermes plc (the “Company”) announced financial results for the three months ended March 31, 2025. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on May 1, 2025 discussing such financial results are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. This information, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes o…